Navigation Links
Genesis Biopharma Appoints L. Stephen Coles M.D., Ph.D. to Board of Directors
Date:2/23/2011

LOS ANGELES, Feb. 23, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC Bulletin Board: GNBP), a biotechnology company developing targeted cancer therapies, today announced the appointment of L. Stephen Coles, M.D., Ph.D. to the Company's Board of Directors.  Dr. Coles has more than four decades experience in healthcare practice and technology management in both government and the private sector.

"Stephen Coles brings exceptional medical, scientific and business experience to the Board of Genesis Biopharma," said Anthony J. Cataldo, President and Chief Executive Officer. "In addition to being a recognized authority in medical technology and biostatistics, he is also a successful entrepreneur and innovator, having founded two high technology companies. His background and expertise will play an important role in the Company's growth."

Dr. Coles is currently a Lecturer in the Department of Chemistry and Biochemistry at the University of California Los Angeles, and at the UCLA Molecular Biology Institute.  Previously he served as Co-Principal Investigator in the Department of Surgery at the UCLA School of Medicine, and as Vice President for Medical Education and Internet Content at The Kronos Group. He is also the co-founder of Image Data Corporation, where he served as Chief Scientist, and Rcommunity.com, Inc., where he was Chief Technical Officer.

About Genesis Biopharma, Inc.

Genesis Biopharma, Inc. is a development-stage biotechnology company engaged primarily in the development of targeted cancer therapies. For more information on the company, visit www.genesis-biopharma.com.

Forward-Looking Statements

The foregoing press announcement contains forward-looking statements that can be identified by such terminology as "expect," "potential," "suggests," "bodes," "may," "should," "could" or similar expressions.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as of the date they are made. The company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.


'/>"/>
SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenesis Biomedical Announces Additions to Board of Directors
2. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
5. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
6. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
7. Genesis Pharmaceuticals Launches New Corporate Website
8. ThermoGenesis Presentation at Rodman & Renshaw Conference
9. Cardiogenesis Reports Third Quarter 2008 Results
10. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
11. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... As Ebola resurfaces in the Democratic ... suspected cases now reported, a new analysis of the Ebola ... correlation between the 2014 and 2017 outbreaks of the disease.  ... 2012-13, which preceded the 2014 outbreak. An analysis of the ... counts in 2014-15, which again precedes the current outbreak in ...
(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... ... celebrates this month its 20th anniversary, marking the occasion with a strong presence ... the meeting’s Welcome Reception and further extends an invitation to all attendees to ...
(Date:5/23/2017)... ... May 23, 2017 , ... Energetiq ... has announced a facility expansion to accommodate its rapid growth. , The renovations ... workspace and renovation of the existing areas. The expansion includes, a state-of-the-art engineering ...
(Date:5/23/2017)... ... 2017 , ... Customers often prefer PLC and network ... METTLER TOLEDO has released two new videos that show how they have solved ... ACT350 into Siemens and Allen Bradley PLCs is easy and fast. ...
Breaking Biology Technology:
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):